<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">24424190</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-0183</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>4-5</Issue>
            <PubDate>
              <Year>2014</Year>
              <Season>Apr-May</Season>
            </PubDate>
          </JournalIssue>
          <Title>Autoimmunity reviews</Title>
          <ISOAbbreviation>Autoimmun Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review.</ArticleTitle>
        <Pagination>
          <StartPage>367</StartPage>
          <EndPage>371</EndPage>
          <MedlinePgn>367-71</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.autrev.2014.01.022</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1568-9972(14)00034-2</ELocationID>
        <Abstract>
          <AbstractText>Autoantibodies are a hallmark in the diagnosis of many systemic autoimmune rheumatic diseases (SARD) including idiopathic inflammatory myopathies (IIM). Based on their specificity, autoantibodies in IIM are grouped into myositis specific (MSA) and myositis associated autoantibodies (MAA). Among the MSA, autoantibodies against aminoacyl-tRNA synthetases (ARS) represent the most common antibodies and can be detected in 25-35% of patients. The presence of ARS and other autoantibodies has become a key feature for classification and diagnosis of IIM and is increasingly used to define clinically distinguishable IIM subsets. For example, anti-ARS autoantibodies are the key features of what has become known as anti-synthetase syndrome (aSS), characterized by multiple organ involvement, primarily interstitial lung disease, often accompanied by myositis, non-erosive arthritis, Raynaud's phenomenon, fever, and "mechanic's hands". Autoantibodies directed to eight different ARS have been described: Jo-1 (histidyl), PL-7 (threonyl), PL-12 (alanyl), OJ (isoleucyl), EJ (glycyl), KS (asparaginyl), Zo (phenylalanyl) and Ha (tyrosyl). Each anti-ARS antibody seems to define a distinctive clinical phenotype. Although several research methods and commercial tests are available, routine testing for anti-ARS autoantibodies (other than anti-Jo-1/histidyl-tRNA synthetase) is not widely available, sometimes leading to delays in diagnosis and poor disease outcomes.</AbstractText>
          <CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mahler</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>INOVA Diagnostics, Inc., San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miller</LastName>
            <ForeName>Frederick W</ForeName>
            <Initials>FW</Initials>
            <AffiliationInfo>
              <Affiliation>NIEHS, National Institutes of Health, DHHS, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fritzler</LastName>
            <ForeName>Marvin J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Calgary, Calgary, Canada. Electronic address: fritzler@ucalgary.ca.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>ZIA ES101074-12</GrantID>
            <Agency>Intramural NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>01</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Autoimmun Rev</MedlineTA>
        <NlmUniqueID>101128967</NlmUniqueID>
        <ISSNLinking>1568-9972</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C035401">SS-A antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.1.1.-</RegistryNumber>
          <NameOfSubstance UI="D000604">Amino Acyl-tRNA Synthetases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C537778">Antisynthetase syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000604" MajorTopicYN="N">Amino Acyl-tRNA Synthetases</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001168" MajorTopicYN="N">Arthritis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009220" MajorTopicYN="N">Myositis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012261" MajorTopicYN="N">Ribonucleoproteins</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autoantibodies</Keyword>
        <Keyword MajorTopicYN="N">Immunoassay</Keyword>
        <Keyword MajorTopicYN="N">Jo-1</Keyword>
        <Keyword MajorTopicYN="N">Myositis</Keyword>
        <Keyword MajorTopicYN="N">Synthetase</Keyword>
      </KeywordList>
      <CoiStatement><b>Competing interests</b>. M. Mahler, is employed at INOVA Diagnostics a manufacturer of autoantibody kits and assays. M.J. Fritzler is a paid consultant of ImmunoConcepts Inc. and INOVA Diagnostics and has received diagnostics gifts in kind from Euroimmun.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24424190</ArticleId>
        <ArticleId IdType="mid">NIHMS560375</ArticleId>
        <ArticleId IdType="pmc">PMC3970575</ArticleId>
        <ArticleId IdType="doi">10.1016/j.autrev.2014.01.022</ArticleId>
        <ArticleId IdType="pii">S1568-9972(14)00034-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7:343–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21654717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13:209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132021</ArticleId>
            <ArticleId IdType="pubmed">21457520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al.  The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Medicine (Baltimore ) 2013;92:223–243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3721421</ArticleId>
            <ArticleId IdType="pubmed">23877355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al.  Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2013;15:335–0335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23591825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2206383</ArticleId>
            <ArticleId IdType="pubmed">17688695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci. 2010;1183:267–287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20146721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghirardello A, Bendo R, Rampudda ME, Bassi N, Zampieri S, Doria A. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev. 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19393203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2013 in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4031026</ArticleId>
            <ArticleId IdType="pubmed">23422076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takato H, Waseda Y, Watanabe S, Inuzuka K, Katayama N, Ichikawa Y, et al.  Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia--with or without PM/DM. Respir Med. 2013;107:128–133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23137883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, Danko K, Vencovsky J, Fisher B, et al.  Anti-PL-7 (Anti-Threonyl-tRNA Synthetase) Antisynthetase Syndrome: Clinical Manifestations in a Series of Patients From a European Multicenter Study (EUMYONET) and Review of the Literature. Medicine (Baltimore) 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22732951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehndiratta P, Mehta S, Manjila SV, Kammer GM, Cohen ML, Preston DC. Isolated necrotizing myopathy associated with ANTI-PL12 antibody. Muscle Nerve. 2012;46:282–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22806380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burford B, Gentry-Maharaj A, Graham R, Allen D, Pedersen JW, Nudelman AS, et al.  Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. Br J Cancer. 2013:10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3670483</ArticleId>
            <ArticleId IdType="pubmed">23652307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cruellas MG, Viana VS, Levy-Neto M, de Souza FH, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo) 2013;68:909–914.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3715024</ArticleId>
            <ArticleId IdType="pubmed">23917652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, et al.  Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009;135:1550–1556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19225060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al.  Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11:739–745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22326685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al.  Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev. 2012;12:210–217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22771754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christopher-Stine L, Robinson DR, Wu CC, Mark EJ. Case records of the Massachusetts General Hospital. Case 37–2012. A 21-year-old man with fevers, arthralgias, and pulmonary infiltrates. N Engl J Med. 2012;367:2134–2146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23190225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunimasa K, Arita M, Nakazawa T, Tanaka M, Tsubouchi K, Konishi S, et al.  The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis. Intern Med. 2012;51:3405–3410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23257529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fritzler MJ. Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun Rev. 2008;7:616–620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18603023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller FW, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci USA. 1990;87:9933–9937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC55288</ArticleId>
            <ArticleId IdType="pubmed">1702223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:350–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22743034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medsger TA, Jr, Dawson WN, Jr, Masi AT. The epidemiology of polymyositis. Am J Med. 1970;48:715–723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5420557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14511932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:337–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15099594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep. 2013;15:349–0349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23794106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts) N Engl J Med. 1975;292:403–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1089199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, et al.  Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol. 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23806844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993;91:2556–2564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC443318</ArticleId>
            <ArticleId IdType="pubmed">8514867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev. 2009;8:632–637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19393201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, et al.  Short-Term and Long-Term Outcome of Anti-Jo1-Positive Patients with Anti-Ro52 Antibody. Semin Arthritis Rheum. 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22078416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman IE, Peene I, Veys EM, De KF. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem. 2002;48:2171–2176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12446473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fritzler MJ, Fritzler ML. The emergence of multiplexed technologies as diagnostic platforms in systemic autoimmune diseases. Curr Med Chem. 2006;13:2503–2512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17017907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bentow C, Swart A, Wu J, Seaman A, Manfredi M, Infantino M, et al.  Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta. 2013 in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23727029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ronnelid J, Helmers SB, Storfors H, Grip C, Ronnblom L, Larsson KF, et al.  Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9:58–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19285154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, et al.  Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 2010;49:2370–2374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20724434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernatsky S, Joseph L, Pineau CA, Belisle P, Boivin JF, Banerjee D, et al.  Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis. 2009;68:1192–1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18713785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain. 1975;98:637–666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1218371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487–1498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1658649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al.  Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22:668–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7791161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Targoff IN, Miller FW, Medsger TA, Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9:527–535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9375282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, Van Venrooij WJ, Voskuyl AE, et al.  Polymyositis: An overdiagnosed entity. Neurology. 2003;61:316–321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12913190</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
